Table III.
Expression levels of β-catenin in HNSCC11A and HNSCC22B cells following incubation with 2 µg/ml lapatinib and gefitinib, as determined by enzyme-linked immunosorbent assay.
| Mean ±SD expression levels of β-catenin, pg/ml (P-value)a | |||
|---|---|---|---|
| Incubation time (h) | Control | Lapatinib | Gefitinib |
| HNSCC11A | |||
| 5 | 6,316.33±2.697.22 | 5,008.33±3,464.97 (0.9288) | 1,262.67±433.66 (0.1231) |
| 24 | 10,557.33±2,958.91 | 12,331.00±1,327.30 (0.8905) | 7,759.67±4,585.48 (0.6567) |
| 96 | 10,774.33±731.52 | 9,692.33±277.49 (0.1350) | 7,774.33±778.50 (0.0003) |
| HNSCC22B | |||
| 5 | 7,587.00±1,848.14 | 6,308.67±1,830.21 (0.7439) | 1,051.33±141.93 (0.0021)b |
| 24 | 7,546.00±1,653.26 | 4,009.67±3,565.12 (0.3053) | 960.33±140.86 (0.0293)b |
| 96 | 55.07±52.2 | 251.83±86.62 (0.6529) | 680.53±133.54 (0.0183)b |
a
P-value vs. negative control (Dunnett's test, n=3)
b
statistically significant differences were observed in HNSCC22B cells upon treatment with gefitinib, at 5, 24 and 96 h post-incubation. HNSCC, head and neck squamous cell carcinoma; SD, standard deviation.